Remove Bicuspid/Mitral Remove Heart Failure Remove Quality of Life
article thumbnail

M-TEER Reduces Cardiovascular Risk, Improves Quality of Life in HF with Mitral Regurgitation

HCPLive

RESHAPE-HF2 shows mitral transcatheter edge-to-edge repair (M-TEER) reduces heart failure hospitalizations and improves quality of life vs optimal medical therapy alone.

article thumbnail

AHA Raises Awareness on HVD

DAIC

If untreated, it can lead to severe complications, including heart failure and death. Key symptoms of aortic stenosis include: Chest pain Shortness of breath Dizziness or fainting Fatigue Rapid or irregular heartbeat Gender Disparities Studies have shown that women and men experience heart valve disease differently.

article thumbnail

FDA Advisory Committee Votes in Favor of Abbott’s First-of-its-kind Triclip System to Treat People with a Leaky Tricuspid Heart Valve

DAIC

Tricuspid regurgitation can put added strain on the heart and lead to other cardiovascular issues, which can significantly worsen a person's quality of life, but historically there have been few treatment options," said Lars Søndergaard , M.D.,

Tricuspid 102
article thumbnail

Edwards’ EVOQUE Valve Replacement System First Transcatheter Therapy to Earn FDA Approval for Tricuspid Valve

DAIC

“Edwards has a long history of leading innovation and pioneering new therapies to address the unmet needs of patients with structural heart disease,” said Daveen Chopra , Edwards’ corporate vice president, transcatheter mitral and tricuspid therapies. “We

Tricuspid 100
article thumbnail

What is new in Heart failure management ? Ultrasonic cardiac re-synchronization : The WiSE -CRT device

Dr. S. Venkatesan MD

In the process, improving the ejection fraction and possibly reducing mitral regurgitation. However, advanced heart failure therapy never means it can be achieved only by state-of-the-art technology. Only few lucky patients end up getting heart transplantation, the ultimate treatment. 2021 May 21;23(5):740-747.

article thumbnail

Abbott Announces FDA Approval of First-of-its-kind Device to Repair Leaky Tricuspid Heart Valve, TriClip

DAIC

Food and Drug Administration (FDA) approval of its TriClip, a first-of-its-kind device to repair leaky tricuspid heart valve, for which more than 1.6 are affected by tricuspid regurgitation, 1 which can severely impact quality of life. Abbott has announced U.S million people in the U.S. are estimated to be affected. and Lynn C.

Tricuspid 105
article thumbnail

Cardiac Dimensions Appoints Satya Shreenivas, MD, as Chief Medical Officer

DAIC

Dr. Shreenivas brings his rich experience in both the clinical and commercial aspects of the structural heart landscape to his new role with Cardiac Dimensions. There, he served as an investigator in many high-profile clinical trials, including several significant structural heart studies.